NEWRON PHARMACEUT. EO-20 (NP5) — Cash Flow-to-Debt Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has a Cash Flow-to-Debt Ratio of 0.63x as of December 2025, meaning its operating cash flow of €32.35 Million could theoretically repay 1% of its total liabilities (€51.19 Million) in one year. See NEWRON PHARMACEUT. EO-20 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
NEWRON PHARMACEUT. EO-20 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for NEWRON PHARMACEUT. EO-20 across 5 annual periods. Also explore NEWRON PHARMACEUT. EO-20 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for NEWRON PHARMACEUT. EO-20 (2021–2025)
Year-by-year debt coverage analysis for NEWRON PHARMACEUT. EO-20. For market capitalisation and broader financial context, see how much is NEWRON PHARMACEUT. EO-20 worth.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.63x | €32.35 Million | €51.19 Million | ▲ +324.1% |
| 2024 | -0.28x | €-17.61 Million | €62.45 Million | ▼ -55.1% |
| 2023 | -0.18x | €-10.14 Million | €55.77 Million | ▲ +16.0% |
| 2022 | -0.22x | €-11.09 Million | €51.23 Million | ▲ +10.4% |
| 2021 | -0.24x | €-11.45 Million | €47.38 Million | — |